Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
BKK:JSP-R's Debt-to-Equity is ranked worse than 50.37% of 1757
companies
in the Consumer Packaged Goods industry
Industry Median: 0.42
vs BKK:JSP-R: 0.43
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
JSP Pharmaceutical Manufacturing (Thailand) PCL Debt-to-Equity Related Terms
JSP Pharmaceutical Manufacturing (Thailand) PCL Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JSP Pharmaceutical Manufacturing (Thailand) PCL Debt-to-Equity vs Consumer Packaged Goods Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R) has a Debt-to-Equity of 0.43 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on JSP Pharmaceutical Manufacturing (Thailand) PCL and its competitors. This is 30% above median its historical median of 0.33. Over the past decade, JSP Pharmaceutical Manufacturing (Thailand) PCL's Debt-to-Equity has ranged from 0.16 to 1.24. According to the industry distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #885 out of 1757 companies in the Consumer Packaged Goods industry, placing it in the top 50.4%.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL's Debt-to-Equity too high?
JSP Pharmaceutical Manufacturing (Thailand) PCL's current Debt-to-Equity of 0.43 is 30% above median its 10-year median of 0.33. Over the past 10 years, this metric has ranged from a low of 0.16 to a high of 1.24. The Consumer Packaged Goods industry median Debt-to-Equity is 0.42. JSP Pharmaceutical Manufacturing (Thailand) PCL's value of 0.43 is 2.4% above this industry median. Based on the distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #885 out of 1757 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, JSP Pharmaceutical Manufacturing (Thailand) PCL has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JSP Pharmaceutical Manufacturing (Thailand) PCL's Debt-to-Equity compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #885 out of 1757 companies for Debt-to-Equity. This places JSP Pharmaceutical Manufacturing (Thailand) PCL in the lower half of its industry. The industry median Debt-to-Equity is 0.42. JSP Pharmaceutical Manufacturing (Thailand) PCL's value of 0.43 is 2.4% above this benchmark. Historically, JSP Pharmaceutical Manufacturing (Thailand) PCL's own Debt-to-Equity has ranged from 0.16 to 1.24 over the past decade. While the company's 10-year median is 0.33 vs. the industry median of 0.42, JSP Pharmaceutical Manufacturing (Thailand) PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Consumer Packaged Goods company?
The median Debt-to-Equity among Consumer Packaged Goods companies is 0.42, based on 1,757 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JSP Pharmaceutical Manufacturing (Thailand) PCL's current Debt-to-Equity of 0.43 is 2.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on JSP Pharmaceutical Manufacturing (Thailand) PCL and its competitors. For the Consumer Packaged Goods industry, the median Debt-to-Equity is 0.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JSP Pharmaceutical Manufacturing (Thailand) PCL's current Debt-to-Equity is 0.43, which is 30% above median its own 10-year median of 0.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL stock overvalued right now?
Based on GuruFocus' analysis, JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿2.18, compared to a current price of ฿1.75 — trading 19.9% below its estimated fair value. The current Debt-to-Equity is 0.43, which is 30% above median its 10-year median of 0.33 and 2.4% above the Consumer Packaged Goods industry median of 0.42. JSP Pharmaceutical Manufacturing (Thailand) PCL's overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R), the current Debt-to-Equity is 0.43 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R) Overvalued in 2026?
Based on GuruFocus' analysis, JSP Pharmaceutical Manufacturing (Thailand) PCL stock appears to be undervalued.
The current stock price of ฿1.75 is trading 19.9% below its estimated GF Value™ of ฿2.18.
GuruFocus considers JSP Pharmaceutical Manufacturing (Thailand) PCL to be Modestly Undervalued.
Key valuation signals for BKK:JSP-R:
Debt-to-Equity: 0.43 (30% above median its 10-year median of 0.33)
GF Value™: ฿2.18 vs. price of ฿1.75 (19.9% below fair value)
Industry Position: 2.4% above the Consumer Packaged Goods median (#885 of 1757)
No single metric tells the full story. See the BKK:JSP-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JSP Pharmaceutical Manufacturing (Thailand) PCL is engaged in producing modern medicine, traditional medicine, herbal products, dietary supplements, medical supplies, and cleaning alcohol under the client's and the company's own trademarks. Maximum revenue for the company is generated from the sale of dietary supplements. The Group's reportable operating segments are: Manufacture and distribution of products under the company's brand name (Own brands), which generate maximum revenue, Manufacture and distribution of products under customers' brand name (OEM), Manufacture and distribution of hemodialysis solution and related medical supplies; and Service, research and development, and healthcare products training. Geographically, it operates principally in Thailand.
82GF Score
Get the complete analysis for BKK:JSP-R
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:JSP-R has been successfully added to your 
